Bispecific T cell engager B-ALL: B cell progenitor acute lymphoblastic leukemia CAR-T: Chimeric antigen receptor T cell CD: Cluster of differentiation CDC: Complement-dependent cytotoxicity CH : Constant region of the heavy chain CL : Constant region of the light chain CLEC12A: C-type...
Accordingly, we developed a bispecific DC-T cell engager (BiCE), a reagent that facilitates physical interactions between PD-1+ T cells and cDC1. BiCE treatment promotes the formation of active dendritic/T cell crosstalk in the tumor and tumor-draining lymph nodes. In vivo, single-cell and ...
Subklewe, M. et al. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE® (bispecific T-cell engager) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) [abstract].Blood134(Suppl. 1), 833 (...
Bispecific T-cell engaging (BITE) antibodies also encounter clinical challenges, including short half-lives requiring continuous infusion and potential toxicities. Methods To address these issues, we developed a lentiviral system to engineer T cells that secrete αB7-H3-αCD3 bispecific engager ...
that contribute to anti-tumor responses, therefore, considerable interest has recently focused on the potential of NK cells for cancer immunotherapies [173]. Bispecific killer cell engager (BiKE) that ligate CD16 on NK cells and a tumor antigen on tumor cells has been developed to activate NK ...
et al. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv. 3, 897–907 (2019). Article CAS PubMed PubMed Central Google Scholar Yun, H. D. et al. Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity ...
et al. Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv. 2, 1580–1584 (2018). PubMed Central Google Scholar Schmohl, J. U., Felices, M., Taras, E., Miller, J. S. & Vallera, D. A. Enhanced ADCC...
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation Nat Cancer, 4 (11) (2023), pp. 1536-1543 CrossrefView in ScopusGoogle Scholar 15 S Mailankody, SM Devlin, J Landa, et al. GPRC5D-targeted CAR T cells fo...
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets Blood, 123 (2014), pp. 3016-3026 View PDFView articleCrossrefView in ScopusGoogle Scholar 16 KL Alderson, PM Sondel Clinical cancer therapy by NK cells via antibody-dependent cell-...
Costa LJ, Wong SW, Bermúdez A, de la Rubia J, Mateos M-V, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter...